Literature DB >> 9219826

Human tenascin-C: identification of a novel type III repeat in oral cancer and of novel splice variants in normal, malignant and reactive oral mucosae.

A J Mighell1, J Thompson, W J Hume, A F Markham, P A Robinson.   

Abstract

Tenascin-C is a mosaic, linear glycoprotein that is up-regulated during many normal and pathological processes involving either cell migration or tissue morphogenesis, such as invasion of malignant cells and wound healing. Human tenascin-C contains 8 consecutive type III fibronectin (TNCfn) domains that are involved in alternative splicing and potentially generate a large number of isoforms that code for tenascin-C proteins with subtly different functions. Human tenascin-C splice variants were investigated by RT-PCR in a range of normal and pathological oral mucosal tissues. A novel, 9th human TNCfn domain involved in alternative splicing was identified. It shares 70% nucleic acid and 55% protein sequence homology with chicken TNCfn-ad2. As in avians, this novel repeat was located between TNCfn-B and TNCfn-ad1 and accordingly was designated human TNCfn-ad2. Human TNCfn-ad2 was detected in only 2 of 10 oral cancers. However, TNCfn-ad2 was absent from 40 normal, reactive, pre-malignant and other oral mucosal specimens investigated. Previous studies have described 8 splice variant transcripts for human tenascin-C. By systematic investigation we identified further novel splice variants for human tenascin-C. Furthermore, our results indicate that many potential splice variants probably do not exist in the tissues investigated. Thus, we have demonstrated that human tenascin-C transcripts generate a complex but selected repertoire of different alternative splice products.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9219826     DOI: 10.1002/(sici)1097-0215(19970717)72:2<236::aid-ijc6>3.0.co;2-s

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

1.  High-molecular tenascin-C as an indicator of atypical cells in oral brush biopsies.

Authors:  O Driemel; R Dahse; A Berndt; H Pistner; S G Hakim; L Zardi; T E Reichert; H Kosmehl
Journal:  Clin Oral Investig       Date:  2006-11-17       Impact factor: 3.573

2.  Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder.

Authors:  Alexander Berndt; Katharina Anger; Petra Richter; Laura Borsi; Simon Brack; Michela Silacci; Marcus Franz; Heiko Wunderlich; Mieczyslaw Gajda; Luciano Zardi; Dario Neri; Hartwig Kosmehl
Journal:  J Cancer Res Clin Oncol       Date:  2006-05-31       Impact factor: 4.553

3.  A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies.

Authors:  Alexander Berndt; Robert Köllner; Petra Richter; Marcus Franz; Astrid Voigt; Angela Berndt; Laura Borsi; Raffaella Giavazzi; Dario Neri; Hartwig Kosmehl
Journal:  Histochem Cell Biol       Date:  2010-03-17       Impact factor: 4.304

Review 4.  Role of tenascins in the ECM of gliomas.

Authors:  Nicole Brösicke; Andreas Faissner
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

5.  Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody.

Authors:  B Carnemolla; P Castellani; M Ponassi; L Borsi; S Urbini; G Nicolo; A Dorcaratto; G Viale; G Winter; D Neri; L Zardi
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

Review 6.  Tenascin-C and carcinoma cell invasion in oral and urinary bladder cancer.

Authors:  Alexander Berndt; Petra Richter; Hartwig Kosmehl; Marcus Franz
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

7.  Association of invasion-promoting tenascin-C additional domains with breast cancers in young women.

Authors:  David S Guttery; Rachael A Hancox; Kellie T Mulligan; Simon Hughes; Sinead M Lambe; J Howard Pringle; Rosemary A Walker; J Louise Jones; Jacqueline A Shaw
Journal:  Breast Cancer Res       Date:  2010-08-02       Impact factor: 6.466

8.  Involvement of large tenascin-C splice variants in breast cancer progression.

Authors:  Takatsugu Tsunoda; Hiroyasu Inada; Ilunga Kalembeyi; Kyoko Imanaka-Yoshida; Mirei Sakakibara; Ray Okada; Koji Katsuta; Teruyo Sakakura; Yuichi Majima; Toshimichi Yoshida
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

9.  B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder?

Authors:  Petra Richter; Markus Tost; Marcus Franz; Annelore Altendorf-Hofmann; Kerstin Junker; Laura Borsi; Dario Neri; Hartwig Kosmehl; Heiko Wunderlich; Alexander Berndt
Journal:  J Cancer Res Clin Oncol       Date:  2009-03-27       Impact factor: 4.553

10.  The role of tenascin-C in tissue injury and tumorigenesis.

Authors:  Kim S Midwood; Gertraud Orend
Journal:  J Cell Commun Signal       Date:  2009-10-17       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.